

## [What Other People Are Saying About Mensing](#)

Friday, June 24, 2011

As we mentioned [yesterday](#), due to Dechert's involvement in litigation concerning the drug at issue in [Pliva, Inc. v. Mensing](#), No. 09-993, [slip op.](#) (U.S. June 23, 2011), we can't comment on the case. But some other people have. Here's a wrap up of what other legal types (not the press) have said.

The [FDA Law Blog](#) channels Harry Carey, "Holy Cow!" Generics win.

[PharmaExec](#) focused on the dissent's claim that preemption "makes generics more dangerous."

The Wall Street Journal's [Law Blog](#) called it a "red letter day" for generic manufacturers. The Journal's [Health Blog](#) mentioned the case, but didn't have all that much to say.

That was all the commentary we picked up from DDLaw's blog roll.

Looking farther afield, we found a couple of paragraphs on the [Forbes Blog](#). We then tried checking out other defense firms.

What we found were slim pickings.

[Duane Morris](#) had a long but pretty much "just the facts" analysis.

[Faegre](#) gave us three paragraphs.

That's it. That was all we found, at least as of this morning.

From the other side, [ATLA goes nuts](#).

By far the most substantive post we found was from the [Law Profs](#), although (unfortunately but predictably) they support the side of unlimited litigation (law students need jobs). With their nose for the arcane, the Profs focused on the court's "non obstante" discussion – the one non-majority (it was 4-4) section of the [Mensing](#) opinion.